The engineers of human souls & academia

Epidemiologia e Psichiatria Sociale

Volumn 16, Issue 3, 2007, Pages 205-211

  Healy, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETANILIDE; ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; DIAMORPHINE; FLUOXETINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; VALPROATE SEMISODIUM;

BIPOLAR DISORDER; CLINICAL PRACTICE; DEPRESSION; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG RESEARCH; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MANIA; MORTALITY; PANIC; PATENT; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; SCHIZOPHRENIA; SCIENTIFIC LITERATURE; SOCIAL PHOBIA;

EID: 34447526418     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x0000230x     Document Type: Review

References (36)

1. Angell M. (2005). The Truth about the Drug Companies. How They Deceive Us and What to Do About It. Random House: New York.
2. Applbaum K. (2004). The Marketing Era. Routledge: New York.
3. Ban T.A. (1987). Prolegomenon to the clinical prerequisite. Psychopharmacology and the classification of mental disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 11, 527-580.
4. Ban T.A. (2006). Academic psychiatry and the pharmaceutical industry. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30, 429-441.
5. Blumsohn A (2006a). Scientific Misconduct Blog. Retrieved June 4, 2007, from http://scientific-misconduct.blogspot.com/
6. Blumsohn A. (2006b). Authorship, ghost-science, access to data and control of the pharmaceutical scientific literature: who stands behind the word? Professional Ethics Report 19(3). Retrieved June 4, 2007, from http://www.aaas.org/spp/sfrl/per/per46.pdf
7. Colton C.W. & Manderscheid R.W. (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventive Chronic Disease 3(2). Retrieved June 4, 2007, from http://www.cdc.gov/pcd/issues/2006/apr/05_0180.htm.
8. Davies H (2001). The role of the private sector in protecting human subjects. Institute of Medicine. Retrieved June 4, 2007, from http://www.acrohealth.org/testimony.php?yr=2001
9. Delay J., Deniker P. &, Ropert R (1955). Etude de 300 dossiers de maladies psychotiques traits par la chlorpromazine en service fermé depuis 1952. Encéphale 528-535.
10. Fava G. (2007). Financial conflicts of interest in psychiatry. World Psychiatric Association Journal 6(1), 19-24.
11. Fish F (1964). The influence of the tranquilizers on the Leonhard schizophrenic syndromes. Encephale 53, 245-249.
12. Fugh-Berman A. (2006). Doctors must not be lapdogs to drug firms. British Medical Journal 333, 1027.
13. Getz K. & De Bruin A. (2000). Breaking the development speed barrier. Drug Information Journal 34, 725-736.
14. Healy D. (1997). The Antidepressant Era. Harvard University Press: Cambridge Mass.
15. Healy D. (2004). Let Them Eat Prozac. New York University Press: New York.
16. Healy D. (2006a). The latest mania. Selling bipolar disorder. PloS Medicine. Retrieved June 4, 2007, from http://dx.doi.org/10.1371/journal. pmed.0030185
17. Healy D. (2006b). Manufacturing Consensus. Culture, Medicine and Psychiatry 30, 135-156.
18. Healy D (2006c). Let them eat Prozac. Retrieved June 4, 2007, from http://www.healyprozac.com/AcademicStalking/default.htm
19. Healy D. (submitted for publication). Trussed in Evidence? Ambiguities at the interface of Clinical Evidence and Clinical Practice. Transcultural Psychiatry.
20. Healy D. & Cattell D. (2003). The Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry 182, 22-27.
21. Healy D., Savage M., Michael P., Harris M., Hirst D., Carter M., Cattell D., McMonagle T., Sohler N. & Süsser E. (2001). Psychiatric bed utilisation: 1896 and 1996 compared. Psychological Medicine 31, 779-790.
22. Healy D., Harris M., Cattell D., Michael P., Chalasanni P. & Hirst D. (2005). Service utilisation in 1896 and 1996: Morbidity and mortality data from North Wales. History of Psychiatry 16, 27-41.
23. Healy D., Harris M., Tranter R., Gutting P., Austin R., Jones-Edwards G. & Roberts A.P. (2006). Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. British Journal of Psychiatry 188, 223-228.
24. Heath I. (2006). Combating disease mongering: daunting but nonetheless essential. PLoS Medicine 3, e146.
25. Joukamaa M., Heliövaara M., Knekt P., Aromaa A., Raitasalo R. & Lehtinen V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry 188, 122-127.
26. Kassirer J. (2005). On the Take. How Medicine's Complicity with Big Business Can Endanger Your Health. Oxford University Press: New York.
27. Keller M.D., Ryan N.D., Strober M., Klein R.G., Kutcher S.P., Birmaher B., Hagino O.R., Koplewicz H., Carlsson G.A., Clarke G.N., Emslie G.J., Feinberg D., Geller B., Kusumakar V., Papatheodorou G., Sack W.H., Sweeney M., Wagner K.D., Weiler E, Winters N.C., Oakes R. & McCafferty J.P. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Journal of American Academy of Child and Adolescent Psychiatry 40, 762-772.
28. Lemmens T. & Freedman B. (2000). Ethics review for sale? Conflict of interest and commercial research review boards. Milbank Quarterly 78, 547-584.
29. Lieberman J.A., Stroop T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
30. Moynihan R. & Cassels A. (2005). Selling Sickness. Nation Books: New York.
31. Petryna A. (2006). Globalizing human subjects research. In Global Pharmaceuticals. Ethics, Markets, Practices (ed. A. Petryna, A. Lakoff and A. Kleinman), pp. 33-60. Duke University Press: Durham.
32. Shepherd M. (1998). Psychopharmacology: specific and non-specific. In The Psychopharmacologists, Vol. 2 (by D. Healy), pp. 237-258. Arnold: London.
33. Thompson J., Baird P. & Downie J. (2001). The Olivieri Report. James Lorimer & Co.: Toronto.
34. th 1991.
35. United States Patent (1992). No. 5,229,382. Date of Patent May 22, 1992. European patent, EP0,454,436, filed on April 24, 1991.
36. th 1993.